A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer

Author： Bayliss Trevor J   Smith Jeff T   Schuster Michael   Dragnev Konstantin H   Rigas James R  

Publisher： Informa Healthcare

ISSN： 1471-2598

Source： Expert Opinion on Biological Therapy, Vol.11, Iss.12, 2011-12, pp. : 1663-1668

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The recombinant humanized anti-IL-6 receptor antibody tocilizumab, an innovative drug for the treatment of rheumatoid arthritis

By Ohsugi Yoshiyuki   Kishimoto Tadamitsu  

Expert Opinion on Biological Therapy, Vol. 8, Iss. 5, 2008-05 ,pp. : 669-681

Informa Healthcare

Access to resources Recommend Favorite

The development of immunotherapies for non-small cell lung cancer

By Salgaller Michael L  

Expert Opinion on Biological Therapy, Vol. 2, Iss. 3, 2002-03 ,pp. : 265-278

Informa Healthcare

Access to resources Recommend Favorite

Cetuximab in non-small cell lung cancer

By Ademuyiwa Foluso O   Hanna Nasser  

Expert Opinion on Biological Therapy, Vol. 8, Iss. 1, 2008-01 ,pp. : 107-113

Informa Healthcare

Access to resources Recommend Favorite

The role of talactoferrin alfa in the treatment of non-small cell lung cancer

By Kelly Ronan J   Giaccone Giuseppe  

Expert Opinion on Biological Therapy, Vol. 10, Iss. 9, 2010-09 ,pp. : 1379-1386

Informa Healthcare

Access to resources Recommend Favorite

A review of vaccine clinical trials for non-small cell lung cancer

By Nemunaitis J   Nemunaitis J  

Expert Opinion on Biological Therapy, Vol. 7, Iss. 1, 2007-01 ,pp. : 89-102

Informa Healthcare

Access to resources Recommend Favorite